ClinicalTrials.gg
RecruitingNCT06015048Updated Aug 5, 2024

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

A Phase 1/2 interventional study of SHR-A1811 combined with Pyrotinib. and SHR-A1811 combined with other antitumor therapies in HER2-expressing Advanced Solid Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-05.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
364
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A1811 combined with other antitumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-A1811 combined with other antitumor therapies for advanced solid tumors.

02

Conditions studied

  • HER2-expressing Advanced Solid Tumors
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written . Have good compliance and cooperated with follow-up visits.
  2. Subjects are older than or equal to 18 years old and younger than or equal to 75 years old on the day of signing the informed consent. Male or female.
  3. score 0-1.
  4. is at least 12 weeks.
  5. or cytologically confirmed or advanced unresectable -expression or Her-2 functional mutations solid tumors.
  6. Provide ≥ 6(or ≥8)sections of formalin-fixed, paraffin-embedded tumor tissue blocks or unstained tumor specimen sections. Sections should be archived within 1 year before the first study treatment or freshly obtained (freshly obtained is preferred).
  7. ≥1 , according to the Response Evaluation Criteria for Solid Tumors () version 1.1. The dose escalation phase allows for the absence of measurable lesions.
  8. Organ function met criteria within 7 days prior to initial administration (No blood component or cell growth factor was used within 14 days before the initial administration):
  9. (LVEF) ≥ 50% at baseline within 28 days prior to initial administration.
  10. Males and women of childbearing age must use reliable from the written informed consent to 7 months after last drug administration (SHR-A1811) or 8 weeks after last drug administration (Pyrotinib) or 6 months after last drug administration (BP102 or Oxaliplatin or Calcium levonofolinate or fluorouracil), the latest time should be taken as final. Women of childbearing age must have had a pregnancy test (serum or urine) with negative results within 7 days prior to initial administration and must not in lactation period.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with untreated or known active . Subjects with a history of meningeal or known active meningeal metastasis.
  2. Have a history of antibody drug conjugate with following characteristics: topoisomerase I inhibitors, including Enhertu (DS-8201a), U3-1402, etc. Part A: Have a history of Her-2 targeted tyrosine-kinase inhibitor (TKI).
  3. Palliative radiotherapy within 14 days prior to initial administration. Subjects who had received systemic anti-tumor therapy within 4 weeks prior to initial administration will not permitted. The interval between the end of small-molecule targeted drugs administration and initial test drug administration must be ≥ 5 half-lives or 7 days (take the longer time). The interval between the end of Chinese patent anti-tumor drug administration and initial test drug administration must be ≥ 2 weeks. Participating in another clinical study of other drugs. The interval between the previous clinical study drug use and this study initial administration is less than 4 weeks or 5 half-lives of previous clinical study drug (take the shorter time).
  4. Toxicity and/or complications of previous interventions were not recovered to ≤ grade 1 or didn't meet this inclusion criteria and exclusion criteria. If investigator determines that the toxicity and/or complications are NCI-CTCAE ≤ grade 2 and there is no safety risk, this subject can be enrolled. For example, patients with type 1 diabetes or hypothyroidism who have been treated with and are stable after hormone replacement therapy.
  5. Have a history of (non-infectious) interstitial lung disease (ILD). Suspected ILD. Other moderate and severe lung diseases that may interfere the detection or management of drug-related pulmonary toxicity and severely affect respiratory function within 3 months before the first test drug administration. Any disease, connective tissue disease, or inflammatory disease with lung involvement.
  6. Patients unable to swallow orally administered medication and other disorders likely to interfere the absorption of the study drugs within 28 days before the first test drug administration.
  7. Patients with moderate and severe ascites of clinical symptoms or moderate to severe pleural effusion or pericardial effusion.
  8. Patients with intestinal obstruction within 6 months prior to the first test drug administration or presence of signs and symptoms of intestinal obstruction (patients can be enrolled if surgical treatment had been performed and the obstruction had been completely resolved).
  9. Have cardiovascular disease.
  10. Previous or combined with other except those have achieved complete remission and do not require or are not expected to require other treatment during the study period within at least 5 years prior to screening, including basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, cervical carcinoma in situ, local prostate cancer, ductal carcinoma in situ after radical surgery, etc (hormone therapy for non-metastatic prostate cancer or breast cancer is allowed) .
  11. Serious infections within 28 days prior to the first test drug administration. Active infections that had received therapeutic intravenous antibiotics within 2 weeks prior to the first test drug administration. Prophylactic antibiotic therapy can be enrolled.
  12. Active or active infection. Active hepatitis B is defined as hepatitis B surface antigen (HBsAg) positive and HBV-DNA ≥10000 copies/ml [2000 IU/ml] during screening. Active hepatitis C is defined as hepatitis C virus antibody positive and HCV-RNA positive during screening. Patients with active pulmonary tuberculosis infection within 1 year before enrolment, or with a history of active pulmonary tuberculosis infection but without regular treatment more than 1 year before enrolment. Has known immunodeficiency disorders, including (HIV) infection, etc. Received attenuated within 28 days of initial administration. Expected use of attenuated live vaccines during the study period.
  13. Major surgery history other than diagnostic or surgery within 28 days prior to initial administration. Minor traumatic surgery within 7 days prior to initial administration. Non-healing wounds. Untreated bone fractures.
  14. Known allergy to any component of SHR-A1811. History of severe allergic reactions to other monoclonal antibody/fusion protein drugs. Part A: known allergy to any component of Pyrotinib.
  15. Female subjects who are pregnant, in lactation period, or planning pregnancy during the study period.
  16. Uncontrolled mental illness and other conditions which will affect the completion of the study, such as alcohol abuse, drug or substance abuse, criminal detention, etc.
  17. Any other conditions that may not eligible to participate in this study according to researchers' judgment.

For Part B1, subjects must not meet any of the following supplementary criteria at the same time, otherwise they will not be enrolled in the study:

1、Presence of grade >1 peripheral neuropathy.

For those who plan to receive BP102 combination therapy, subjects must not meet any of the following supplementary criteria at the same time, otherwise they will not be enrolled in the study:

  1. Bleeding tendency, coagulation dysfunction, or high risk of thrombosis.
  2. Poorly controlled hypertension after medication (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg in the case of regular anti-hypertensive therapy) and prior hypertensive crisis or hypertensive encephalopathy. Severe cerebrovascular diseases and clinically significant vascular diseases.
  3. Severe cerebrovascular disease, including cerebrovascular accident (CVA), (TIA), and significant vascular disease (including but not limited to aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to enrollment;
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
364 participants (estimated)

Study arms

  • Experimental
    Part A: Intervention: Drug: SHR-A1811 combined with Pyrotinib

    Drug: SHR-A1811 combined with Pyrotinib.

  • Experimental
    Part B1: Intervention: Drug: SHR-A1811 combined with other antitumor therapies

    Drug: SHR-A1811 combined with other antitumor therapies

Interventions

  • DrugSHR-A1811 combined with Pyrotinib.

    SHR-A1811 combined with Pyrotinib

  • DrugSHR-A1811 combined with other antitumor therapies

    SHR-A1811 combined with other antitumor therapies

06

What researchers measure

Primary outcomes

  1. Part A: Maximally Tolerated Dose (MTD),)(Phase ⅠB).

    Time frame: From the first dose to the last dose, about 11 months

  2. Part A: recommended phase 2 dose (RP2D)(Phase ⅠB).

    Time frame: From the first dose to the last dose, about 11 months

  3. Part A: Adverse Events (Phase ⅠB)

    Time frame: From the first dose to the last dose, about 11 months

  4. Part A: Objective Response Rate (ORR) (Phase Ⅱ)

    Time frame: From the first dose to the last dose, about 11 months

Secondary outcomes

  1. Part A: ORR (Phase ⅠB).

    Time frame: From the first dose to the last dose, about 11 months.

  2. Part A: Disease Control Rate (DCR) (Phase ⅠB and Phase Ⅱ)

    Time frame: From the first dose to the last dose, about 11 months

  3. Part A: Duration of Response (DoR) (Phase ⅠB and Phase Ⅱ)

    Time frame: From the first dose to the last dose, about 11 months

  4. Part A: Progression-free survival (PFS) (Phase ⅠB and Phase Ⅱ)

    Time frame: From the first dose to the last dose, about 13 months.

  5. Part A: Overall survival (OS) (Phase ⅠB and Phase Ⅱ)

    Time frame: From the first dose to the last dose, about 13 months

  6. Part A: Adverse Events (PhaseⅡ).

    Time frame: about 11 months.

07

Study locations

15 of 15 sites recruiting
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
    Recruiting
    • Yubei Sun · Principal investigator
  • Peking University Cancer Hospital & Institute-Department of Gastrointestinal Oncology
    Beijing, Beijing 100142, China
    Recruiting
    • Lin Shen · Principal investigator
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400016, China
    Recruiting
    • Tao Zhang · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hospital
    Nanning, Guangxi 530021, China
    Recruiting
    • Yongqiang Li · Principal investigator
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Recruiting
    • Fengbing Zhang · Principal investigator
  • Harbin Medical University Cancer Hospital-The Eighth Department of Internal Medicine
    Harbin, Heilongjiang, China
    Recruiting
    • Yanqiao Zhang · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
    Recruiting
    • Yan Zhao · Principal investigator
  • The First Affiliated Hospital of Zhengzhou University-Department of Medical Oncology
    Zhengzhou, Henan 450052, China
    Recruiting
    • Hong zong · Principal investigator
  • Hubei Cancer Hospital-Department of Abdominal Oncology
    Wuhan, Hubei 430079, China
    Recruiting
    • Xinjun Liang · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410031, China
    Recruiting
    • Zhenyang Liu · Principal investigator
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Xiaodong Peng · Principal investigator
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330200, China
    Recruiting
    • Hua Wang · Principal investigator
  • Shanxi Provincial Cancer Hospital-Gastroenterology Department
    Taiyuan, Shanxi 030013, China
    Recruiting
    • Wenhui Yang · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710061, China
    Recruiting
    • Aili Suo · Principal investigator
  • Tianjin Medical University Cancer Institute and Hospital-Department of digestive oncology
    Tianjin, Tianjin 300060, China
    Recruiting
    • Hongli Li · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Nov 2026, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2023
First posted
Aug 29, 2023
StartActual
Aug 11, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Dec 29, 2026
Last update
Aug 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06015048
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Aug 11, 2023
Primary completion
Nov 2026 (estimated)
Completion
Dec 29, 2026 (estimated)
Last update
Aug 5, 2024

Study contacts

Zhengjin Zhang
Contact
zhengjin.zhang.zz79@hengrui.com
+0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion